Dr. Qiu is a Full-time researcher of Beijing Swarma Natural Science Research Center. She graduated from the Yangzhou University, 2003. Received Master's degree in preventive veterinary medicine in 2006 and Ph.D. at molecular genetics in oncology in 2009 from the PLA Academy of Military Medical Sciences (AMMS) . Engaged in the Research and Development (R&D) of therapeutic antibody drugs in AMMS from 2009 to 2019. She was one of the key leads of the R&D research and IND filling of an innovative anti-tumor antibody drug Ametumumab (up to Phase II).
EMAIL：qiuweiyi@swarma.org
Publications/Patents(recent)
WY Qiu, S Wang, C Zhang, XY Yu, JL Ma, P Du, YQ Zheng, B Pang, XB Pang, ZW Sun. A novel antiEGFR mAb Ame55 with lower toxicity and better efficacy than cetuximab when combined with Irinotecan. J Immunol Res. 2019 Jan 13;201.
W. Qiu, S. Wang. A Study on the Low Toxicity and High Efficacy of a Novel Fully Humanized AntiEGFR AntibodyA2C1. BIT’s 7th Annual International congress of antibodies-2015. April 25-28, Nanjing, China. (Oral Presentation)
XY Yu, WY Qiu, F Long, XP Yang, C Zhang, L Xu, HY Chang, P Du, XJ Hou, YZ Yu, DD Zeng, S Wang, ZW Sun. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety. Biochimie 151 (2018): 54 - 66.
Du P, Xu L, Qiu W, Zeng D, Yue J, Wang S, Huang P, Sun Z. A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus. MAbs. 2015 Sep 3;7(5):969-80.
Chen L, Li W, Qiu W, Ren W, Li Q, Han B, Zhou L, Cheng L, Zhang H, Ye Q. RSRC1 SUMOylation enhances SUMOylation and inhibits transcriptional activity of estrogen receptor β. FEBS Lett. 2015 Jun 4;589(13):1476-84.